FDA Accepts Aradigm’s New Drug Application for Linhaliq to Treat Non-CF Bronchiectasis

News

A new drug application (NDA) submitted by Aradigm for Linhaliq (inhaled ciprofloxacin) was recently accepted for filing with priority review status by the U.S. Food and Drug Administration (FDA). The NDA ... Read more

March 4, 2015March 4, 2015

P. aeruginosa Colonies Have the Highest Influence on Clinical Status in Non-CF Bronchiectasis

News

Results from a recent study published in the International Journal of Mycobacteriology showed that, compared to other pathogens, colonization with P. aeruginosa has the highest influence on the functional, clinical and radiological ... Read more